Loading...
•
Sep 30, 2024
Beauty Health Q3 2024 Earnings Report
Reported third quarter net sales of $78.8 million and improved profitability due to strategic initiatives.
Key Takeaways
BeautyHealth reported Q3 2024 net sales of $78.8 million, a decrease of 19.1% compared to Q3 2023. However, the company saw improved profitability with an increase in gross margin and adjusted EBITDA, driven by operational excellence initiatives and disciplined expense management. The company also revised its full year net sales guidance lower and improved its adjusted EBITDA guidance.
Net sales were $78.8 million, a decrease of (19.1)% compared to Q3 2023, due to lower delivery systems net sales.
Gross margin was 51.6% compared to (12.9)% in Q3 2023, primarily due to the absence of charges associated with the Syndeo Program in 2023 and lower inventory related charges.
Net loss was $(18.3) million compared to net loss of $(73.8) million in Q3 2023, primarily due to costs associated with the Syndeo Program in 2023.
Adjusted EBITDA was $8.1 million compared to $9.1 million in Q3 2023, primarily due to lower net sales offset by higher gross margin and lower operational spend.
Beauty Health
Beauty Health
Beauty Health Revenue by Geographic Location
Revenue by Geographic Location
Americas Revenue
CapyFin.comAPAC Revenue
CapyFin.comEMEA Revenue
CapyFin.com Forward Guidance
The Company revised its full year net sales guidance lower due to continued pressure on delivery systems sales and improved its adjusted EBITDA guidance to reflect stronger profitability in the third quarter.
Positive Outlook
- Improved Q3 2024 gross margin performance
- Reduction in operational spend
- Assumes no material deterioration in general market conditions
- Excludes any unannounced acquisitions
- Excludes any unannounced dispositions or financings.
Challenges Ahead
- Revised full-year net sales guidance reflects continued downward pressure on delivery systems sales.
Revenue & Expenses
Visualization of income flow from segment revenue to net income